Family History
187 articles
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.
A New Triple Combination for Tumors with BRCA1/2 or PALB2 Mutations
A clinical trial is comparing a two-drug combination with a three-drug combination to see which works better for genetic mutations.
Developing a Screening Test for Pancreatic Cancer
One focus of research for Dr. Anirban Maitra is to develop a simple screening test for pancreatic cancer, to provide an earlier diagnosis of the disease.
Vitamin C Plus Standard Chemo Improves Overall Survival
Dr. Joseph Cullen believes intravenous vitamin C can help pancreatic cancer patients and his most recent trial results back this up.
New Potential Early Detection Trial for Type 2 Diabetics
Dr. Anna Bergamaschi explains the new Avantect blood test for the early detection of pancreatic cancer in people with type 2 diabetes.
New Immunotherapy Strategy Aimed at High-Risk Population
Dr. Neeha Zaidi is the lead investigator of an immunotherapy trial using a vaccine for people at high risk for pancreatic cancer.
Liquid Biopsies: What You Should Know
Three different liquid biopsy blood tests are under development or now available for pancreatic and other cancers.
Will New-Onset Diabetes Provide a Way to Detect Pancreatic Cancer Earlier?
Dr. Anirban Maitra, Dr. Suresh Chari, and others are looking at the relationship between new-onset diabetes and pancreatic cancer.
AACR Annual Meeting 2021 Highlights
Let’s Win and the Lustgarten Foundation bring you the pancreatic cancer research highlights of the 2021 AACR Annual Meeting,
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.